PE20190421A1 - Metodo para prevenir o tratar la perdida de la audicion - Google Patents

Metodo para prevenir o tratar la perdida de la audicion

Info

Publication number
PE20190421A1
PE20190421A1 PE2019000369A PE2019000369A PE20190421A1 PE 20190421 A1 PE20190421 A1 PE 20190421A1 PE 2019000369 A PE2019000369 A PE 2019000369A PE 2019000369 A PE2019000369 A PE 2019000369A PE 20190421 A1 PE20190421 A1 PE 20190421A1
Authority
PE
Peru
Prior art keywords
hearing loss
prevent
treat hearing
pamapimod
difluorophenoxy
Prior art date
Application number
PE2019000369A
Other languages
English (en)
Inventor
Alexander Bausch
Original Assignee
Support Venture Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Support Venture Gmbh filed Critical Support Venture Gmbh
Publication of PE20190421A1 publication Critical patent/PE20190421A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Referido a un metodo para prevenir o tratar la perdida de la audicion e inhibir la degeneracion o muerte de celulas ciliadas que consiste en utilizar una combinacion farmaceutica que comprende: a) un agonista de PPAR tal como pioglitazona; b) un inhibidor de la quinasa p38 de formula I, donde un compuesto seleccionado es 6-(2,4-difluorofenoxi)-2-[3-hidroxi-1-(2-hidroxietil)-propilamino]-8-metil-8H-pirido[2,3-(i]pirimidin-7-ona (pamapimod); y opcionalmente c) uno o mas diluyentes, excipientes o portadores farmaceuticamente aceptables.
PE2019000369A 2016-08-17 2017-08-15 Metodo para prevenir o tratar la perdida de la audicion PE20190421A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16184541 2016-08-17

Publications (1)

Publication Number Publication Date
PE20190421A1 true PE20190421A1 (es) 2019-03-19

Family

ID=56740115

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019000369A PE20190421A1 (es) 2016-08-17 2017-08-15 Metodo para prevenir o tratar la perdida de la audicion

Country Status (18)

Country Link
US (1) US20190209568A1 (es)
EP (1) EP3500258A1 (es)
JP (1) JP2019528273A (es)
KR (1) KR20190039142A (es)
CN (1) CN109562105A (es)
AU (1) AU2017313296A1 (es)
BR (1) BR112019003006A2 (es)
CA (1) CA3033887A1 (es)
CL (1) CL2019000410A1 (es)
CO (1) CO2019001402A2 (es)
EA (1) EA201990220A1 (es)
IL (1) IL264625A (es)
MA (1) MA45981A (es)
MX (1) MX2019001819A (es)
PE (1) PE20190421A1 (es)
PH (1) PH12019550015A1 (es)
SG (1) SG11201900776TA (es)
WO (1) WO2018033543A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021524493A (ja) * 2018-07-13 2021-09-13 キナラス アーゲー 線維性疾患を予防または処置するためのＰＰＡＲアゴニストおよびｐ３８キナーゼ阻害剤の組合せ物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR240698A1 (es) 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US5421818A (en) 1993-10-18 1995-06-06 Inner Ear Medical Delivery Systems, Inc. Multi-functional inner ear treatment and diagnostic system
TWI249401B (en) * 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
US20020151491A1 (en) * 2000-11-28 2002-10-17 Jian-Dong Li Composition and method for treating the over-production of mucin in diseases such as otitis media using an inhibitor of MUC5AC
RU2269527C2 (ru) * 2001-02-12 2006-02-10 Ф.Хоффманн-Ля Рош Аг Производные пиридопиримидинов, способы их получения и фармацевтическая композиция на их основе
DE602004005238T2 (de) 2003-11-13 2007-11-08 F. Hoffmann-La Roche Ag Hydroxyalkylsubstituierte pyrido-7-pyrimidin-7-one
US8870826B2 (en) 2004-05-24 2014-10-28 Auris Medical Llc Combined otic aspirator and medication dispenser
WO2008151992A2 (en) 2007-06-15 2008-12-18 F. Hoffmann-La Roche Ag A novel process for the preparation of 3-amino-pentan-1,5-diol
AU2016217937A1 (en) * 2015-02-11 2017-08-24 Support-Venture Gmbh Method of preventing or treating hearing loss
PE20190376A1 (es) * 2016-06-08 2019-03-08 Support Venture Gmbh Combinaciones farmaceuticas para el tratamiento del cancer

Also Published As

Publication number Publication date
PH12019550015A1 (en) 2019-07-24
EA201990220A1 (ru) 2019-08-30
AU2017313296A1 (en) 2019-02-14
IL264625A (en) 2019-02-28
CN109562105A (zh) 2019-04-02
MX2019001819A (es) 2019-06-13
EP3500258A1 (en) 2019-06-26
CL2019000410A1 (es) 2019-06-28
US20190209568A1 (en) 2019-07-11
SG11201900776TA (en) 2019-03-28
CA3033887A1 (en) 2018-02-22
BR112019003006A2 (pt) 2019-05-14
WO2018033543A1 (en) 2018-02-22
CO2019001402A2 (es) 2019-02-19
MA45981A (fr) 2019-06-26
JP2019528273A (ja) 2019-10-10
KR20190039142A (ko) 2019-04-10

Similar Documents

Publication Publication Date Title
MX2017009571A (es) Inhibidores heterociclicos de itk para el tratamiento de la inflamacion y cancer.
NZ742208A (en) Topical pharmaceutical formulations for treating inflammatory-related conditions
CL2018001145A1 (es) Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria
CO2017012267A2 (es) Compuestos de naftiridina como inhibidores de la quinasa jak
EA201991556A1 (ru) Ингибиторы фосфодиэстеразы и способы лечения микробной инфекции
MX2021000148A (es) Inhibidores eterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer.
EA201692249A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA201991884A3 (ru) Ингибиторы g12c kras
NZ739893A (en) Fused pyrimidine compound or salt thereof
CO2017003838A2 (es) Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos
BR112016024057A2 (pt) inibidores de quinases heterocíclicos
MX2017016655A (es) Formulaciones oftalmicas de inhibidores de tirosina quinasa, metodos de uso de las mismas y metodos de preparacion de las mismas.
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
MX2019003143A (es) Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico.
AU2018347307A1 (en) Heterocyclic compounds and uses thereof
EA201692487A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
ZA201904522B (en) Heterocyclic inhibitors of mct4
EA201692266A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA201692268A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA201692265A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
CO2019002246A2 (es) Compuesto heterocíclico nitrogenado bicíclico
MX2018004664A (es) Antagonistas de ep4.
MX2019003317A (es) Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk).
PH12019501461A1 (en) Pharmaceutical composition of benzenesulfonamide derivatives for treatment of adenoid cystic carcinoma
EA201991412A1 (ru) Ингибиторы поли(адф-рибоза)полимеразы (parp)